Firms

S32

San Francisco, California · Cambridge, Massachusetts · San Francisco Bay Area · Palo Alto, California, US

signal.nfx.com

s32.com

linkedin.com

Venture firm founded in 2017, formerly branded Section32, investing in technology and healthcare. The S32 exact record and separately existing GoldiSection32 record remain distinct pending deliberate identity/duplicate review.

Founded: 2017
Type: Venture capital

Funds3

S32 Fund 6, LP2025-09-022025-09-02—
SEC Form D/A signed 2025-08-29, filed 2025-09-02: USD 600000000 offering, USD 413550000 sold, USD 186450000 remaining, 91 investors. Regulatory offering/sales amounts are not a final-close commitment or current AUM. Latest-known vehicle in sources checked.
Section 32 Fund 52023-10-052023-10-05$525M
USD 525 million closed; announcement 2023-10-05. Software/AI emphasis. Transaction-counsel release was search-index accessible in research.
Section 32 Fund 42021-11-042021-11-04$740M
Approximately USD 740 million closed, oversubscribed; announcement 2021-11-04. Historical all-stage technology/healthcare fund, not current AUM.

Team

Allison Pavlick S32, Principal	$16M$3M – $30M	San Francisco, California
Nathan Wu S32, Partner	$15M$3M – $20M	San Francisco, California
Derrick Chow S32, Investor (Signal team listing)	$150K$100K – $5M	San Francisco Bay Area
Steve Kafka S32, General Partner	$25K$10K – $50K	Cambridge, Massachusetts
Wesley Tillu S32, Partner	$25K$10K – $50K	San Francisco, California

Operations and support

Alice CheungPartner, Talent

Andrew Conrad, PhDGeneral Partner

Andy HarrisonGeneral Partner, CEO

Ayesha AroraVenture Partner

Bayan AlizadehPartner

Bill MarisGeneral Partner, Founder

Celine LeOperations

Evalynne DacayananOperations

Isabelle RuddyAccounting Manager

Jennie ChanController

Kenzo FongPartner, Product

Kimberly ShihPartner, Talent

Linda BoormanOperations

Mike Pellini, MDGeneral Partner

Nick SmithChief Investor Relations Officer

Nina LabattChief Financial Officer & Chief Operating Officer

Olivia LuAssistant Controller

Robyn VillaroOperations

Tane KimVenture Partner

Tom ZhangHead of Data

Co-investing

Investments

$97M2025-11-13	Beacon Biosignals	S32, GV, Hemant Taneja, Section 32
$37M2026-08-26	Faro AI	S32, Merck Global Health Innovation Fund, General Catalyst, Northpond Ventures, Zetta Venture Partners, Ankona Capital, PTX Capital, Polaris Partners
$14M2026-03-18	Autoscience	General Catalyst, S32, MaC Venture Capital, Toyota Ventures, Perplexity Fund, Section 32
$40M2026-03-18	RunSybil	Vinod Khosla, Khosla Ventures, Anthology Fund, Menlo Ventures, Conviction Partners, S32, Section 32
$40M2026	RunSybil	Khosla Ventures, Menlo Ventures, S32, Conviction Partners, Section 32
$—2025-12-16	Culture Biosciences	S32, Northpond Ventures, Cultivian Sandbox Ventures, Synthesis Capital, Section 32
$300M2025-12-01	BFL	Bain Capital, Temasek Holdings (Private) Limited, BroadLight Capital, Earlybird Venture Capital, Samsung Next, Salesforce Ventures, Creandum, Bain Capital Ventures, General Catalyst, S32, Cherry Ventures, Lux Capital, Northzone, Notion Capital, Section 32
$115M2025-11-20	Aspen Neuroscience	ARCH Venture Partners, S32, Axon Partners Group, OrbiMed, Cormorant Asset Management, Lifeforce Capital, Kite, a Gilead Company
$115M2025-11-20	Aspen Neuroscience	ARCH Venture Partners, S32, Axon Partners Group, Cormorant Asset Management, Lifeforce Capital, Avon Ventures, Kite, a Gilead Company, Section 32
$35M2025-09-04	Octave Bioscience	S32, The Blue Venture Fund, Casdin Capital, Northpond Ventures, Merck Global Health Innovation Fund, Hikma Ventures, Byers Capital, Novartis
$35M2025-09-04	Sola Security	S32, Section 32, New Era Capital Partners, M12, Glilot Capital Partners, S Capital VC, Wesley Tillu
$100M2025-06-02	Infleqtion	S32, Glynn Capital, SAIC Capital, Section 32
$25M2025-05-07	Inductive	S32, Obvious Ventures, Amino Collective, Lux Capital, Andreessen Horowitz (a16z) Bio + Health, Character Capital, Andreessen Horowitz, Section 32
$93M2025-04-23	Endor Labs	Lightspeed, Coatue Management LLC, DFJ Growth, Salesforce Ventures, S32, Citi Ventures, Section 32
$93M2025-03-25	Character Biosciences	S32, Innovation Endeavors, Casdin Capital, Catalio Capital Management, aMoon, Sanofi Ventures, Jefferson Life Sciences
$30M2025-03-11	Sola	S32, Glilot Capital Partners, S Capital VC, Section 32
$—2024-10-22	TollBit	Lightspeed, S32, Section 32
$14M2024-10-16	SunBird Bio	S32, EDBI, Polaris Partners, Eli Lilly and Company, ClavystBio, Section 32
$60M2024-10-09	Basecamp	S32, Singular, Redalpine, Section 32
$40M2024-01-17	Pomelo	S32, Monashees, TQ Ventures, Endeavor, General Catalyst, Index Ventures
$60M2024	Basecamp Research	S32, Singular, Redalpine, True Ventures, Section 32
$70M2023-08-03	Endor Labs	Lightspeed, Coatue Management LLC, S32, Dell Technologies Capital, Section 32
$30M2023-07-26	Octave Bioscience	Northpond Ventures, Casdin Capital, S32, The Blue Venture Fund, Echo Health Ventures, Merck Global Health Innovation Fund, Hikma Ventures
$20M2023-02-08	Faro AI	General Catalyst, Elena Viboch, S32, Northpond Ventures, Polaris Partners, Zetta Venture Partners
$50M2023-01-24	Forward Networks	S32, The Goldman Sachs Group, Inc., BDT & MSD Partners, Threshold Ventures, Bessemer Venture Partners, Omega Funds, Section 32
$25M2022-11-01	MedCrypt	S32, ENIAC Ventures, Dolby Family Ventures, Johnson & Johnson Innovation, Intuitive Ventures, Anzu Partners, Section 32
$45M2022-10-11	Stairwell	S32, Section 32, Angel Invest, Accel, Lux Capital, Gradient Ventures, Sequoia Capital, Sequoia, Eric Schmidt, Darian Shirazi
$50M2022-08-23	Inworld AI	S32, Founders Fund, Kleiner Perkins, CRV, M12, Micron Ventures, Intel Capital, Section 32, Izhar Armony
$75M2022-07-20	BigHat Biosciences	S32, Vineeta Agarwala, Steve Kafka
$147M2022-05-09	Aspen Neuroscience	ARCH Venture Partners, Mirae Asset, EDBI, Alexandria Venture Investments, S32, Lifeforce Capital
$5M2022-04-05	Nirvana (Parallel)	S32, Coinbase Ventures, StarkWare, Section 32
$125M2022-02-16	Cohere	S32, Radical Ventures, Index Ventures, Tiger Global Management, LLC, Section 32
$75M2022-01-20	ONI	ARCH Venture Partners, Casdin Capital, S32, Axon Partners Group, The Vertical Group, Oxford Science Enterprises, Section 32
$300M2021-12-07	Freenome	Vasudev Bailey, Bain Capital, Catalio Capital Management, DCVC, Roche Venture Fund, S32, Pura Vida Investments, Cowen Healthcare Investments, Section 32
$25M2021-11-17	MedArrive	S32, Section 32, Kleiner Perkins, Leaps by Bayer, 7wire Ventures, Redesign Health, Refinery Ventures
$25M2021-11-09	Mekonos	S32, TDK Ventures, Sands Capital, Imaginary Ventures, TDR Capital, ICU Ventures, Section 32
$215M2021-11-09	Arbor Biotechnologies	ARCH Venture Partners, TCV, Temasek Holdings (Private) Limited, Tao Capital Partners, Redpoint Ventures, S32, Illumina Ventures, Section 32
$8M2021-10-13	ScienceIO	S32, Section 32, Quiet Capital, Dorm Room Fund, Todd & Rahul Capital, Earl Grey Capital, Toba Capital, Jeffrey Silverstein, Oliver Cameron
$50M2021-10-07	Gretel	S32, Greylock Partners, Anthos Capital, Moonshots Capital, Section 32
$50M2021-10-06	Wise Systems	S32, Gradient Ventures, Tiger Global Management, LLC, Cavallo Ventures, Prologis, Section 32, Zach Bratun-Glennon
$156M2021-09-30	Formation Bio	S32, Casdin Capital, Dragoneer Investment Group, Thrive Capital, Sound Ventures, Spark Capital, Sequoia, Felicis, Section 32
$40M2021-09-07	Cohere	S32, Radical Ventures, Index Ventures, Section 32, Pieter Abbeel
$15M2021-06-08	Faro AI	S32, Northpond Ventures, Polaris Partners, Zetta Venture Partners
$100M2021-04-15	C2i Genomics	S32, Casdin Capital, Gobi Partners, Duquesne Family Office, NFX, Silver Lake, Section 32
$10M2021-04-14	Legacy	Bain Capital, TQ Ventures, S32, Y Combinator, Thrive Capital, FirstMark Capital, Bain Capital Ventures, Section 32
$47M2021-03-23	Meatable	S32, GV, Vertex Pharmaceuticals, BlueYard Capital, Gates Foundation, Humboldt Fund, Section 32
$32M2020-12-17	Octave Bioscience	Northpond Ventures, Echo Health Ventures, Casdin Capital, S32, The Blue Venture Fund
$46M2020-07-15	Glympse Bio	S32, Section 32, Temasek Holdings (Private) Limited, Redpoint Ventures, CRV
$70M2020-04-01	Aspen Neuroscience	ARCH Venture Partners, S32, OrbiMed, Domain Associates, Frazier Healthcare Partners, Section 32
$35M2020-02-05	Vineti	S32, Casdin Capital, Threshold Ventures, Lifeforce Capital, Kite, a Gilead Company, Hive Ventures, Section 32
$3M2020-01-31	Legacy	Bain Capital, S32, Y Combinator, Bain Capital Ventures, Section 32
$120M2020	Genedx	S32, Connecticut Innovations, Oak HC/FT, Moore Strategic Ventures, Decheng Capital, Blackstone Inc., Section 32
$6M2019-12-12	Aspen Neuroscience	ARCH Venture Partners, Alexandria Venture Investments, S32, Axon Partners Group, OrbiMed, Domain Associates, Section 32
$160M2019-07-24	Freenome	Vasudev Bailey, S32, DCVC, Roche Venture Fund, T. Rowe Price, GV, BrightEdge, Section 32
$25M2019-02-14	Teckro	Founders Fund, S32, Real Ventures, Northpond Ventures, Sands Capital, Section 32
$5M2019-02-12	Culture Biosciences	S32, Section 32, Refactor Capital, Y Combinator, Verily
$90M2018-07-24	Metromile	S32, New Enterprise Associates, Future Fund, Index Ventures, Intact Ventures, Tokio Marine Future Fund, Section 32
$50M2018-07-17	Dialpad	ICONIQ Capital, S32, Scale Venture Partners, GV, Iconiq Capital, LLC, SoftBank Vision Fund, Amasia, Felicis, Section 32, Work-Bench, Marc Andreessen, Jonathan Lehr
$14M2018-07-12	Octave Bioscience	The Blue Venture Fund, Echo Health Ventures, S32
$50M2017-10-16	LimeBike	S32, Section 32, Coatue Management LLC, Franklin Templeton, GGV Capital, AME Cloud Ventures, 35V
$14M2017-10-12	Kobalt	S32, Section 32
$100M2017-08-10	Coinbase	S32, Battery Ventures, Greylock Partners, Institutional Venture Partners, Spark Capital, Draper Associates, Section 32
$160M2016	Freenome	S32, DCVC, Roche Venture Fund, T. Rowe Price, Andreessen Horowitz, GV, Section 32
$—Unknown date	Metaphysic	S32, Winklevoss Capital Management
$170MUnknown date	Lime	Bain Capital, GGV Capital, S32, GV, Institutional Venture Partners, Alphabet Inc., Bain Capital Ventures
$33M2024-03-26	Brightside Health	S32, Village Global, Time BioVentures, Mousse Partners, Triventures, Section 32

team@apexlogos.ai16 hours ago
Investment-fund research reviewed 2026-10-06. Publicly identified funds, dates, amounts and fundraising status are below. Undisclosed commitments remain unknown; this is not a complete register of private SPVs or parallel entities. Fund sizes, vintage and status | Vehicle | Amount and status | Date and support | | --- | --- | --- | | Section 32 Fund 4 | Approximately **USD 740 million, closed**, oversubscribed. Individual fund amount, not AUM or a check size. | 2021-11-04, [firm release](https://www.prnewswire.com/news-releases/section-32-raises-740-million-venture-fund-301416494.html). | | Section 32 Fund 5 | **USD 525 million, closed**, 2023 vintage. | 2023-10-05, [Law360 contemporaneous reporting](https://www.law360.com/articles/1729749/section-32-vc-firm-clinches-525m-ai-focused-fund), [transaction counsel Gunderson Dettmer](https://www.gunder.com/print/v2/content/1726/section-32-announces-525m-fund-5.pdf?lang=en), whose closing announcement was search-index accessible; direct PDF retrieval failed. | | S32 Fund 6, LP | **USD 600 million total offering; USD 413,550,000 sold; USD 186,450,000 remaining**, 91 investors. A 2025 Delaware venture capital fund with William J. Maris named as managing member of its general partner. These are issuer-reported offering/sales figures, not verified final-close commitments or current AUM. | [SEC Form D/A](https://www.sec.gov/Archives/edgar/data/2058574/000205857425000002/xslFormDX08/primary_doc.xml), signature 2025-08-29; filing 2025-09-02 reported by [filing index](https://altstreet.investments/edgar/2058574). Direct SEC text read and amounts verified. | Fund 6 is the **latest-known vehicle found in the sources checked**, while Fund 5 is the latest final close verified here. Searches for newer 2025–2026 funds did not establish a later final close; do not promote the Fund 6 target to a closed amount. Earlier funds exist but their final sizes were not individually reverified. The Fund 4 release reported **AUM over USD 1.8 billion as of 2021-11-04**; that dated total is not current AUM and should not be added to later fund amounts. Current AUM and reliable current check range remain unverified. Funds recorded in Adex after this review: | Fund | Disclosed amount | Announcement / filing date | | --- | --- | --- | | Section 32 Fund 4 | USD 740000000 | 2021-11-04 | | Section 32 Fund 5 | USD 525000000 | 2023-10-05 | | S32 Fund 6, LP | Undisclosed / unverified | 2025-09-02 |
team@apexlogos.ai16 hours ago
Match research 2026-10-06 / S32 / sha256:4d0cf32a0f87e00871c618ad7107d4b34628e2431fac53aa60942ddba99dc026 / part 2 of 2 Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats. | **Aspen Neuroscience** | Patient-derived iPSC neuron replacement, genomics and personalized cell therapy for Parkinson's disease; deep biotechnology. | Official company investor history names Section 32 in seed/A/B and S32 in **USD 115 million Series C, November 2025**. | [Official investor relations, undated; accessed 2026-10-06](https://aspenneuroscience.com/investor-relations/). | An additional independently verified deep-biotech example is **BigHat Biosciences**: Section 32 led its **USD 75 million Series B announced 2022-07-20**; the company combines machine learning and a wet-lab platform to engineer antibody therapeutics. [Transaction counsel Wilson Sonsini, 2022-08-12](https://www.wsgr.com/en/insights/wilson-sonsini-advises-bighat-biosciences-on-ip-and-licensing-matters-related-to-dollar75-million-series-b.html). This is antibody-engineering infrastructure, not verified direct neurotechnology. Other snapshot candidates, such as Arbor Biotechnologies, Freenome, Culture Biosciences and AI model developers, warrant transaction-level review before treating this table as an exhaustive portfolio. Ordinary enterprise SaaS, payments and mental-health service companies have not been classified as deep tech solely because they appear in the snapshot. ## Named neurotechnology and adjacent neurological investments **Beacon Biosignals — verified direct neurotechnology.** Its 2025-11-13 company release describes the Waveband device measuring brain electrical activity directly through EEG and AI models producing neurophysiological biomarkers for clinical research, diagnosis and treatment selection. S32 is explicitly a backer of the USD 86 million Series B. On **2026-04-06** the company announced an extension bringing the same round to **USD 97 million** and cumulative funding above USD 132 million. The extension release reiterates S32 among the prior syndicate, while specifically naming other new investors; it **does not prove S32 invested additional extension capital**. Do not sum $86 million and $97 million as separate rounds. [Original company announcement](https://beacon.bio/news/beacon-biosignals-raises-86m-to-accelerate-ai-driven-insights-into-brain-health); [extension announcement](https://beacon.bio/news/beacon-biosignals-upsizes-series-b-to-over-97-million). **Aspen Neuroscience — neuron replacement biotechnology, separately classified.** This is direct neuronal cell therapy rather than a recording/stimulation device or BCI. The official company history names Section 32 in a USD 6.5 million seed, USD 70 million Series A in early 2020, USD 147.5 million Series B announced 2022-05-09 (current investor history rounds it to USD 147 million) and S32 in a USD 115 million Series C in November 2025. The seed was publicly announced 2019-12-12 in the snapshot, while the current company history links it to its 2018 founding; avoid asserting the closing day from those two statements. [Official investor history](https://aspenneuroscience.com/investor-relations/); [Official 2022-05-09 Series B release](https://www.prnewswire.com/news-releases/aspen-neuroscience-announces-147-5-million-series-b-financing-led-by-gv-lyfe-capital-and-revelation-partners-301541979.html). **Octave Bioscience — adjacent precision neurology diagnostics.** A company Business Wire release syndicated by BioSpace on **2025-09-05** names S32 among existing investors in its closed **USD 35.6 million Series C equity** financing. Its MSDA test measures disease activity for multiple sclerosis, with a Parkinson's diagnostics pipeline; this is biomarker-based neurological disease management, not evidence of a BCI or neural stimulation device. Keep the separately announced **USD 15.5 million SVB term loan** distinct from venture equity and S32 attribution. [Company release syndicated by BioSpace, 2025-09-05](https://www.biospace.com/press-releases/octave-bioscience-announces-35m-series-c-financing-to-accelerate-commercial-momentum). **Sunbird Bio — adjacent blood-based neurological diagnostics.** A **2024-10-16** company Business Wire announcement identifies S32's continued participation in **USD 14 million financing**, with ClavystBio, Polaris, Lilly and EDBI. The technology targets neurological diseases including Alzheimer's and Parkinson's as well as cancer; classify it as diagnostics, not direct recording/stimulation neurotechnology. The release does not assign a Series label. [Company announcement syndicated by Citybiz](https://www.citybiz.co/article/613463/sunbird-bio-closes-14-million-financing/). The snapshot’s “additional $14 million” [BioSpace company-release link](https://www.biospace.com/press-releases/sunbird-bio-raises-additional-14-million-to-advance-broadest-blood-based-diagnostic-platform-in-alzheimers-disease-and-other-neurological-disorders) is dated 2024-10-17 and identifies the same investors, amount and purpose; it appears to syndicate the same financing a day later. Preserve the publication-date difference rather than create a second round. **Neuralink — attribution unresolved, excluded from the verified transaction list.** Its name appears on the current S32 homepage and Andy Harrison's Signal profile. The official homepage also explicitly distinguishes investments made “Prior to S32,” and the text extraction does not reliably associate each logo with that category. Neither a company funding announcement naming S32 nor a specific S32 round/date was established here. A personal profile and scraped investor databases are insufficient to settle whether this is firm capital, personal investment or previous-employer activity. Review before adding any firm investment. No CTRL-labs investment was verified. ## Conflicts, gaps and concrete later Adex review notes 1. Review identity duplication with `GoldiSection32`; preserve IDs until a human-approved reconciliation. Current branding supports S32 as display-name alias. 2. Record Fund 4 and Fund 5 as separate closed funds; Fund 6 as a dated offering with reported sales, not $600 million closed. Current AUM is missing. 3. Audit snapshot investment `amount` fields: many equal total round sizes, e.g. Freenome USD 160 million. These are not verified S32 check amounts. Individual contribution generally remains undisclosed. 4. Snapshot Freenome Series B is dated both 2019-07-24 and 2016; the latter conflicts with the firm's 2017 founding and the linked $160 million Series B narrative. Do not retain 2016 uncritically. Snapshot contains potential duplicates/aliases such as Basecamp/Basecamp Research, RunSybil entries and Sola/Sola Security. 5. Beacon Biosignals already appears in the S32 snapshot with a November 2025 date and Signal investor-profile source; replace weak attribution evidence with the primary company announcement during later review. Review the verified November 2025 Series B and April 2026 same-round extension, preserving amounts and attribution caveats. 6. Correct Octave's missing date to the supported September 2025 announcement/close, keeping equity and debt separate. BioSpace publication is 2025-09-05; the September financing date is supported, while an exact closing day is not established by this syndication alone. 7. Mekonos company announcement verifies 2021-11-09; differently dated syndicated releases need not represent separate rounds. Do not assign S32 lead status from its participation. 8. Preserve neurotechnology distinctions: Beacon direct EEG; Aspen neuronal cell therapy; Octave/Sunbird neurological diagnostics; Brightside is an adjacent mental-health care service lead, not verified direct neural technology. 9. Review current team roles against official pages before replacing snapshot records. Signal has apparently outdated associate/general-partner labels and personal investing histories; firm homepage portfolio also includes prior-firm track records. 10. Research is focused and substantive rather than exhaustive round-by-round validation of all 61 snapshot participations. Exact fund vehicles, firm check sizes, current AUM, Neuralink attribution and all newer closings remain unresolved. Source access failures are noted above rather than treated as negative evidence. Core claims were rechecked on 2026-10-06 after using the existing GoldiSection32 report as leads. Direct retrieval failed for the exact S32 Signal page and some PDFs; alternate Signal/profile pages, company releases and indexed transaction-counsel announcements supplied the stated evidence. URLs retain access date 2026-10-06. Dated announcements retain publication dates; undated pages retain the access date. This document supplies review evidence only and authorizes no MCP Patch, database change or commit.
team@apexlogos.ai16 hours ago
Match research 2026-10-06 / S32 / sha256:4d0cf32a0f87e00871c618ad7107d4b34628e2431fac53aa60942ddba99dc026 / part 1 of 2 Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats. # S32 / Section 32 — S32 - Exact Adex ID: `S32` - Adex webpage: https://adex.page/firms/S32 - Official website: https://www.s32.com/ - Research date and source access date: **2026-10-06** - Status: research complete for this exact record; unresolved points are explicitly identified below. No Adex/database changes made. ## Identity and summary The Adex record named Section 32 corresponds to the venture firm now branded **S32**. Its official site identifies AI, computational biology, physical AI, infrastructure, cybersecurity and enterprise as current focus areas. It describes a concentrated approach with substantial support for a small number of companies. [Official homepage, undated; accessed 2026-10-06](https://www.s32.com/). The S32 baseline leaves its founding year null and includes Bill Maris as founder in an imported team role; the [2021-11-04 official Fund 4 release](https://www.prnewswire.com/news-releases/section-32-raises-740-million-venture-fund-301416494.html) independently identifies Bill Maris as founder and inception in 2017. This is a substantive deep-tech investor with independently attributable quantum hardware, microscopy, cell-engineering and brain-signal investments. **Beacon Biosignals is a verified direct neurotechnology investment.** Aspen Neuroscience, Octave Bioscience and Sunbird Bio are separately classified below as neuron-replacement biotechnology or adjacent neurological diagnostics. The newest fund vehicle located is Fund 6, with a $600 million offering and $413.55 million sold in a 2025 SEC amendment; that does not establish a $600 million final close. A possible duplicate record named GoldiSection32 should be reviewed alongside this record by the later Adex reviewer. This file preserves `S32` exactly; `GoldiSection32` is a separate apparent duplicate requiring later identity review. No records have been merged or edited. ## Adex and NFX Signal starting evidence The saved read-only MCP snapshot `_sources/S32.adex.json`, retrieved 2026-10-06, contains a short “Signal profile (S32)” description, official site and Goldilocks links, San Francisco/Cambridge/Bay Area/Palo Alto locations, 27 role records and 61 investment participations. Its evidence field explicitly links Beacon’s April 2026 extension and its sectors contain EEG. The Signal team snapshot, dated 2026-09-09, lists Derrick Chow, Steve Kafka, Allison Pavlick, Wesley Tillu and Nathan Wu; imported Goldilocks roles expand that list and can duplicate people or historical titles. Its check minimum, maximum and sweet spot are null. Investment leads include Aspen Neuroscience, Infleqtion, ONI, Mekonos, Arbor Biotechnologies, Freenome, Culture Biosciences, Cohere, Octave Bioscience and Sunbird Bio; this existing data is evidence to audit rather than independent confirmation. The baseline NFX link, https://signal.nfx.com/firms/s32, returned an internal error in the browsing tool. An alternate [Signal firm page](https://signal.nfx.com/firms/section-32) was directly accessible, although rendered content varied between calls. Indexed material associates Andy Harrison, Mike Pellini, Steve Kafka and Ayesha Arora with Section 32 and lists Seed, Series A and Series B sector categories, including biotech, medical devices, AI and cybersecurity. It displays $25,000 sweet spots and $10,000–$50,000 ranges on some profiles; those small profile figures are **not verified firm check sizes**. [Andy Harrison's Signal profile](https://signal.nfx.com/investors/andy-harrison_1) associates him with numerous investments, including Neuralink, and lists S32/Section 32 leadership. These personal-profile affiliations do not establish a specific firm round or remove prior-employer attribution risk. All Signal pages are undated, accessed 2026-10-06; underlying full investment records require sign-in. ## Fund sizes, vintage and status | Vehicle | Amount and status | Date and support | | --- | --- | --- | | Section 32 Fund 4 | Approximately **USD 740 million, closed**, oversubscribed. Individual fund amount, not AUM or a check size. | 2021-11-04, [firm release](https://www.prnewswire.com/news-releases/section-32-raises-740-million-venture-fund-301416494.html). | | Section 32 Fund 5 | **USD 525 million, closed**, 2023 vintage. | 2023-10-05, [Law360 contemporaneous reporting](https://www.law360.com/articles/1729749/section-32-vc-firm-clinches-525m-ai-focused-fund), [transaction counsel Gunderson Dettmer](https://www.gunder.com/print/v2/content/1726/section-32-announces-525m-fund-5.pdf?lang=en), whose closing announcement was search-index accessible; direct PDF retrieval failed. | | S32 Fund 6, LP | **USD 600 million total offering; USD 413,550,000 sold; USD 186,450,000 remaining**, 91 investors. A 2025 Delaware venture capital fund with William J. Maris named as managing member of its general partner. These are issuer-reported offering/sales figures, not verified final-close commitments or current AUM. | [SEC Form D/A](https://www.sec.gov/Archives/edgar/data/2058574/000205857425000002/xslFormDX08/primary_doc.xml), signature 2025-08-29; filing 2025-09-02 reported by [filing index](https://altstreet.investments/edgar/2058574). Direct SEC text read and amounts verified. | Fund 6 is the **latest-known vehicle found in the sources checked**, while Fund 5 is the latest final close verified here. Searches for newer 2025–2026 funds did not establish a later final close; do not promote the Fund 6 target to a closed amount. Earlier funds exist but their final sizes were not individually reverified. The Fund 4 release reported **AUM over USD 1.8 billion as of 2021-11-04**; that dated total is not current AUM and should not be added to later fund amounts. Current AUM and reliable current check range remain unverified. ## Investment stages and mandate The 2021 Fund 4 announcement explicitly says the fund invests **across all stages** at the intersection of technology and healthcare. Fund 5's 2023 counsel announcement emphasizes software and AI. The current homepage confirms sector focus and concentration but does not explicitly enumerate stages. Thus the supported description is **historically multi-stage, including seed through later venture**, with a current concentrated technology strategy; do not imply a fresh 2026 explicit seed-to-growth mandate based solely on an old release. Verified transactions below include seed, Series A, B and C; those demonstrate history rather than guaranteed current eligibility. ## Named verified deep-tech investments All amounts below are **total investee financing rounds**, not S32's contribution; individual firm checks and named fund vehicles are undisclosed. | Company | Technology rationale | Verified firm attribution, round and date | Source | | --- | --- | --- | --- | | **Infleqtion** | Atom-based quantum computing, sensing and precision timing: direct physical/quantum technology. | Company names S32 among backers of its **USD 100 million Series C**, announced **2025-06-02**. The firm’s individual contribution is undisclosed. | [Official financing release](https://ir.infleqtion.com/news-events/press-releases/detail/108/infleqtion-raises-100m-to-scale-atom-based-quantum-solutions-for-national-security-and-next-generation-intelligent-systems). | | **ONI / Oxford Nanoimaging** | Super-resolution microscopy and the desktop Nanoimager for observing single molecules in cells: advanced scientific instrumentation. | Section 32 participated in **USD 75 million Series B**, closed and announced **2022-01-20**, led by ARCH and Casdin. | [Transaction counsel Wilson Sonsini, 2022-01-20](https://www.wsgr.com/en/insights/wilson-sonsini-advises-oni-on-dollar75-million-series-b.html). | | **Mekonos** | MEMS, microfluidics and integrated silicon system-on-chip for targeted molecular delivery into cells; cell/gene therapy engineering infrastructure. | Section 32 named as a new institutional investor in **USD 25 million Series A**. Company release dated **2021-11-09**, consistent with the S32 snapshot. Firm is a participant, not one of the three named leads. | [Official Mekonos release, 2021-11-09](https://www.prnewswire.com/news-releases/biotech-startup-mekonos-raises-oversubscribed-25-million-round-to-overcome-pharma-industrys-cell--gene-therapy-delivery-hurdles-301419310.html). | | **Beacon Biosignals** | Wearable EEG plus AI analysis of direct brain electrical signals; also qualifies as direct neurotechnology. | S32 explicitly named in **USD 86 million Series B**, **2025-11-13**. | [Official release](https://beacon.bio/news/beacon-biosignals-raises-86m-to-accelerate-ai-driven-insights-into-brain-health). See neurotechnology detail below. |
team@apexlogos.ai28 days ago
MATCH